SCHEMBL3580327

SCHEMBL3580327

Nc1cc(Cl)c(CC(=O)O)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
AKR1B1 P15121 2/20 0.39
CA2 P00918 1/20 0.39
CXCL8 P10145 4/20 0.39
CAMK2A Q9UQM7 5/20 0.37
CYP2C9 P11712 1/20 0.37
CHRM1 P11229 1/20 0.37
SLC9A1 P19634 1/20 0.37
AKR1B10 O60218 1/20 0.37
UGT1A9 O60656 1/20 0.37
TRPA1 O75762 1/20 0.37
ABCB11 O95342 1/20 0.37
MT-CO2 P00403 1/20 0.37
TTR P02766 1/20 0.37
ALB P02768 1/20 0.37
UGT1A6 P19224 1/20 0.37
UGT1A1 P22309 1/20 0.37
PTGS1 P23219 1/20 0.37
CXCR1 P25024 1/20 0.37
ADRA1A P35348 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17622509 0.88 GAA (0.42) GAAAKR1B1CA2CXCL8CAMK2A
SCHEMBL5357198 0.83 AKR1B1 (0.40) GAAAKR1B1CA2CXCL8CAMK2A
SCHEMBL4837065 0.83 AKR1B1 (0.45) AKR1B1CA2CXCL8CAMK2ACYP2C9
SCHEMBL4549702 0.79 GAA (0.53) GAACXCL8CHRM1
SCHEMBL7714917 0.79 GAA (0.54) GAACYP2C9
SCHEMBL19181631 0.78 SIGMAR1 (0.43) GAACYP2C9SLC9A1
SCHEMBL14793743 0.78 CA2 (0.53) GAAAKR1B1CA2CXCL8CAMK2A
SCHEMBL7164323 0.76 ABCB11 (0.40) AKR1B1CA2CXCL8CAMK2ACYP2C9
SCHEMBL72627 0.75 SMN1; SMN2 (0.41) GAACYP2C9
SCHEMBL11164004 0.75 CA2 (0.50) GAAAKR1B1CA2CXCL8CAMK2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100076202-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US disclosed
US-20100076202-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US disclosed
US-20100076202-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US disclosed
US-7345179-B2 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-18 US disclosed
US-7345179-B2 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-18 US disclosed
US-7345179-B2 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-18 US disclosed
US-20070149607-A1 Method for producing pyrrolidine derivative DAICHI PAHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
US-20070149607-A1 Method for producing pyrrolidine derivative DAICHI PAHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
US-20070149607-A1 Method for producing pyrrolidine derivative DAICHI PAHARMACEUTICAL CO., LTD. (JP) 2007-06-28 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070149606-A1 Process for producing phenylacetic acid derivative DAIICHI PHARMACEUTICAL CO.,LTD. (JP) 2007-06-28 US disclosed
US-20070105935-A1 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105935-A1 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105935-A1 Process for producing pyrrolidine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US disclosed
EP-1698611-A1 PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
EP-1698621-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed
EP-1623975-A1 PROCESS FOR PRODUCING PYRROLIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076202-A1 METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE ALDH18A1, PLAAT4, ACSL4 GAA 588/4885AKR1B1 1345/4885CA2 4104/4885
US-20070149607-A1 Method for producing pyrrolidine derivative ALDH18A1, PLAAT4, ACSL4 GAA 588/4885AKR1B1 1345/4885CA2 4104/4885
US-20070105935-A1 Process for producing pyrrolidine derivative ACSL4, ALDH18A1, LTA GAA 746/4885AKR1B1 317/4885CA2 2085/4885
US-20070149606-A1 Process for producing phenylacetic acid derivative UGT1A4, VPS4B, CYP3A4 GAA 102/4885AKR1B1 784/4885CA2 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.